Background In order to improve the sensitivity of neuroprotective trials in multiple sclerosis (MS) using brain atrophy measures we assessed whether it was possible to predict those patients who had high rates of change in brain volume.
Methods 22 primary progressive MS (PPMS) patients and seven healthy controls had multiple imaging measures assessed (total brain and regional volumes, cervical spinal cord area, single voxel spectroscopy of the corpus callosum (CC) and thalamus, diffusion tensor and magnetisation transfer imaging). Subsequent percentage brain volume change (PBVC) over 1 year was correlated with (a) baseline measures, (b) baseline measures adjusted for disease duration and estimated onset values to give a “prior rate of change” for each measure at baseline.
Results Only baseline CC volume was found to correlate using robust regression with PBVC (r=0.518 p=0.033). This correlation improved when an estimated prior rate of change in CC volume was used (r=0.624 p=0.01). A cut off of 2%/year loss in CC volume would have removed all patients who had subsequent PBVCs <1% and only exclude 2/11 (18.1%) of those who had PBVCs >1%.
Conclusion Baseline measures of the corpus callosum volume can preselect a subgroup of patients whose PBVC will be greater over the subsequent year. This baseline measure can be performed on the same image used to calculate subsequent PBVC. This could improve the efficiency in phase II neuroprotective trials in MS.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.